Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.70 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18978451 | 1.00 | SPHK1 (0.70) | SPHK1SPHK2GAAHPGDHRH3 | |
| SCHEMBL18978575 | 1.00 | SPHK1 (0.70) | SPHK1SPHK2GAAHPGDHRH3 | |
| SCHEMBL13761356 | 0.95 | GAA (0.64) | SPHK1SPHK2GAAHPGDHRH3 | |
| SCHEMBL18978464 | 0.85 | SPHK1 (0.70) | SPHK1SPHK2GAAHPGDHRH3 | |
| SCHEMBL6281922 | 0.85 | SPHK1 (0.60) | SPHK1SPHK2THRATHRB | |
| SCHEMBL15935942 | 0.85 | SPHK1 (0.67) | SPHK1SPHK2 | |
| SCHEMBL19732173 | 0.85 | SPHK1 (0.70) | SPHK1SPHK2THRATHRB | |
| SCHEMBL15935933 | 0.85 | SPHK1 (0.67) | SPHK1SPHK2 | |
| SCHEMBL18978683 | 0.83 | SPHK1 (0.67) | SPHK1SPHK2THRATHRBL3MBTL1 | |
| SCHEMBL1164411 | 0.83 | SPHK1 (0.64) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040215-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | Université Toulouse III - Paul Sabatier (FR) | 2021-02-11 | — | — | US | disclosed |
| US-20190031757-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2019-01-31 | — | — | US | disclosed |
| US-9908849-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031757-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | CD274, PDCD1, PDCD1LG2 | SPHK1 96/4885SPHK2 270/4885GAA 2334/4885 |
| US-20210040215-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | CD274, PDCD1, PDCD1LG2 | SPHK1 96/4885SPHK2 270/4885GAA 2334/4885 |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885SPHK2 1/4885GAA 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.